1 of 1
Story summary
- Former U.S. Senator Ben Sasse used his extended cancer treatment to call for community ties, AI regulation, and long-term policy planning.
- He receives the drug daraxonrasib from Revolution Medicines, which cut his tumor volume 76% and extended his life expectancy beyond the three-to-four-month prognosis, with median survival of 13 months.
- Senate colleagues Mark Warner and Senate majority leader John Thune praised his bipartisan approach and said his voice is missed.
